BGLC vs CLOV vs HUM vs QDEL

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Humana Inc. (HUM) offers the better valuation at 25. 1x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Humana Inc.

(HUM) delivered a total return of -43. 3%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: HUM returned +76. 1% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Humana Inc.

(HUM) is the lower-risk stock at 0. 61β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 273% more volatile than HUM relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: QuidelOrtho Corporation grew EPS 45. 4% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Humana Inc.

(HUM) is the more profitable company, earning 0. 9% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HUM leads at 1. 1% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — QDEL leads at 46. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

4x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 59. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QDEL: 57. 8% to $17. 00.

In this comparison, HUM (1.

4% yield) pays a dividend. BGLC, CLOV, QDEL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Humana Inc.

(HUM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 1. 4% yield). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HUM: +76. 1%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BGLC is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock; QDEL is a small-cap quality compounder stock. HUM pays a dividend while BGLC, CLOV, QDEL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.